Vitiligoid lesions, however, occur more frequently with anti-PD-1 agents than with other immunotherapies (overall incidence of 3
Vitiligoid lesions, however, occur more frequently with anti-PD-1 agents than with other immunotherapies (overall incidence of 3.4%) previously used in melanoma, including […]